NCT04639310Phase 3Terminated

XEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic Encephalopathy

Study sponsor: Xenon Pharmaceuticals Inc. · XENE

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2023-05-16Actual

Enrollment · participants8Actual

Source updated2024-08-23Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied

Epilepsy; Epilepsy in Children; Epilepsy; Seizure; Disease; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Epileptic Syndromes

Treatments or interventions studied

XEN496DrugAlso known as ezogabine, retigabine
PlaceboDrug

Primary outcomes · main study measures

measure: Percent Change From Baseline in Monthly (28 Day) Countable Motor Seizure Frequency During the Blinded Treatment Period; description: Parent/caregiver seizure diary record will be used to assess frequency, type and duration of seizure activity; timeFrame: From baseline to the end of the double-blind, 12 week treatment period (maintenance)

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history